Maud Maho-Vaillant - JoVE Visualize

Showing results (21-30 of 22) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 22 results.

Lancet (London, England)|March 27, 2017

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.

JAMA Dermatology|March 19, 2020

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.

Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 22 results.

Lancet (London, England)|March 27, 2017

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.

JAMA Dermatology|March 19, 2020

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.

Pageof 3